194 related articles for article (PubMed ID: 28948197)
21. Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats.
Ke HZ; Crawford DT; Qi H; Pirie CM; Simmons HA; Chidsey-Frink KL; Chen HK; Jee WS; Thompson DD
Bone; 1999 Jan; 24(1):41-7. PubMed ID: 9916783
[TBL] [Abstract][Full Text] [Related]
22. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate Pre-Treatment Diminishes the Therapeutic Benefits of Teriparatide in Japanese Osteoporotic Patients.
Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H
Tohoku J Exp Med; 2016 May; 239(1):17-24. PubMed ID: 27150954
[TBL] [Abstract][Full Text] [Related]
24. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
25. Effects of the combination of vitamin K and teriparatide on the bone metabolism in ovariectomized rats.
Nagura N; Komatsu J; Iwase H; Hosoda H; Ohbayashi O; Nagaoka I; Kaneko K
Biomed Rep; 2015 May; 3(3):295-300. PubMed ID: 26137225
[TBL] [Abstract][Full Text] [Related]
26. Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide.
Makino A; Takagi H; Takahashi Y; Hase N; Sugiyama H; Yamana K; Kobayashi T
Calcif Tissue Int; 2018 Sep; 103(3):289-297. PubMed ID: 29725706
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis.
Kamanda-Kosseh M; Shiau S; Agarwal S; Kondapalli A; Colon I; Kil N; Bucovsky M; Lappe JM; Stubby J; Shane E; Cohen A
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38605469
[TBL] [Abstract][Full Text] [Related]
28. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.
Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao DS; Miller PD; Woodson GC; Lindsay R; Binkley N; Wan X; Ruff VA; Janos B; Taylor KA
J Clin Endocrinol Metab; 2012 Aug; 97(8):2799-808. PubMed ID: 22701017
[TBL] [Abstract][Full Text] [Related]
29. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
[TBL] [Abstract][Full Text] [Related]
30. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis.
Ebina K; Hashimoto J; Kashii M; Hirao M; Kaneshiro S; Noguchi T; Tsukamoto Y; Yoshikawa H
J Bone Miner Metab; 2017 Jan; 35(1):91-98. PubMed ID: 26762133
[TBL] [Abstract][Full Text] [Related]
31. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
32. Bone Density After Teriparatide Discontinuation With or Without Antiresorptive Therapy in Pregnancy- and Lactation-Associated Osteoporosis.
Lee S; Hong N; Kim KJ; Park CH; Lee J; Rhee Y
Calcif Tissue Int; 2021 Nov; 109(5):544-553. PubMed ID: 34037833
[TBL] [Abstract][Full Text] [Related]
33. Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
Iwaniec UT; Samnegård E; Cullen DM; Kimmel DB
Bone; 2001 Oct; 29(4):352-60. PubMed ID: 11595618
[TBL] [Abstract][Full Text] [Related]
34. Effect of Time of Administration of Teriparatide on Bone Mineral Density in Glucocorticoid-Induced Osteoporosis.
Mastaglia SR
J Clin Densitom; 2017; 20(4):513-515. PubMed ID: 28579148
[TBL] [Abstract][Full Text] [Related]
35. Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats.
Khajuria DK; Razdan R; Mahapatra DR
J Orthop Sci; 2014 Jul; 19(4):646-56. PubMed ID: 24668309
[TBL] [Abstract][Full Text] [Related]
36. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
37. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat.
Gasser JA; Ingold P; Venturiere A; Shen V; Green JR
J Bone Miner Res; 2008 Apr; 23(4):544-51. PubMed ID: 18072878
[TBL] [Abstract][Full Text] [Related]
38. The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study.
Park CH; Yoo JI; Choi CH; Suh YS
BMC Musculoskelet Disord; 2020 Nov; 21(1):751. PubMed ID: 33189148
[TBL] [Abstract][Full Text] [Related]
39. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.
Kondo H; Okimoto N; Yoshioka T; Akahoshi S; Fuse Y; Ogawa T; Okazaki Y; Katae Y; Tsukamoto M; Yamanaka Y; Kawasaki M; Sakai A
J Bone Miner Metab; 2020 Nov; 38(6):894-902. PubMed ID: 32656645
[TBL] [Abstract][Full Text] [Related]
40. Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: comparison between iliac crest and lumbar vertebra in ewes.
Portero-Muzy NR; Chavassieux PM; Bouxsein ML; Gineyts E; Garnero P; Chapurlat RD
Bone; 2012 Oct; 51(4):714-9. PubMed ID: 22796591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
